In today’s briefing:
- Havells India (HAVL IN) | Instant Gratification?
- Enzychem Lifesciences Corp (183490 KS): Picked New Drug Development as Future Growth Engine
- Elastic: Beat and Raise. $2B in Total Revenue in FY25
Havells India (HAVL IN) | Instant Gratification?
- We believe Havells India (HAVL IN) has chosen the route of instant gratification by not increasing prices and gaining market share for Lloyd this AC Season.
- After-Sales Service and aspirational value for the Lloyd brand is poor, there is no brand loyalty in the segments Lloyd operates in and is price sensitive.
- Increased prices and course correction by Voltas Ltd (VOLT IN) could result in HAVL giving up some of its recent market share gains building a stronger Bear case for HAVL.
Enzychem Lifesciences Corp (183490 KS): Picked New Drug Development as Future Growth Engine
- Enzychem Lifesciences Corp (183490 KS) is eyeing on its lead innovative drug candidate, EC-18 for long-term sustainable growth driver. EC-18 is in late-stage clinical trial for couple of indications.
- EC-18 is in phase 2 clinical trial for the treatment of chemoradiation-induced oral mucositis (CRIOM), an acute inflammation of the oral mucosa following systemic chemoradiation therapy.
- Currently, CRIOM has no approved therapies. Enzychem Lifesciences has filed for FDA breakthrough therapy designation for EC-18 in CRIOM, which will enable designing of phase 3 study.
Elastic: Beat and Raise. $2B in Total Revenue in FY25
- Elastic NV (ESTC US) reported stronger than expected 4QFY22 results, and management provided guidance for FY25 total revenue of $2 billion.
- The net expansion rate was 140%+ for Elastic Cloud in 4QFY22, and the company expects cloud revenue to exceed 50% of total revenue by 4QFY24.
- Elastic NV (ESTC US) appears well-positioned to outperform across observability and security market segments. Management was confident in achieving growth objectives in FY23 and beyond.
Related tickers: Havells India (HVEL.NS)
Before it’s here, it’s on Smartkarma
